Bladder Cancer Stage II Clinical Trial
Official title:
Radiogenomics of Muscle Invasive Bladder Cancer
Verified date | April 2024 |
Source | Cedars-Sinai Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder cancer.
Status | Terminated |
Enrollment | 11 |
Est. completion date | April 1, 2024 |
Est. primary completion date | September 9, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients must be > 18 years of age. 2. Patient must have a sessile mass noted within the bladder on cystoscopy or imaging worrisome for bladder cancer, specifically MIBC. 3. Patient must agree to undergo staging which will include mp-4D MRI HR-DWI of the pelvis in addition to standard axial imaging of the abdomen. 4. Patient must be agreeable to undergo planned TURBT as part of the normal treatment course. 5. Patients must not have known or suspected primary urothelial carcinoma of the ureter, urethra, or renal pelvis. 6. Patients must not have known distant metastatic disease (e.g. pulmonary or hepatic metastases). Subjects with malignant lymphadenopathy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadenectomy with the goal of complete resection of all malignant disease are allowed. 7. Patients must not have had prior definitive treatment for bladder cancer. 8. Patients must not have clinically significant active infection or uncontrolled medical condition that would preclude participation in study. 9. Patients must not have any active malignancy other than urothelial carcinoma of the bladder that, in the opinion of the treating investigator, which could interfere with protocol treatment. 10. Patient must have adequate renal function: Serum creatinine < 2 mg/dL OR calculated CrCl > 30ml/min. 11. Patients must not have allergy or contraindication for MRI contrast/contrast dye. 12. Patients must not be under treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to TURBT. 13. Patient must not be adverse to undergo radical cystectomy as part of the normal treatment course if found to have MIBC. 14. Patients must have the ability to understand and willingness to sign a written informed consent. Exclusion Criteria: 1. Persons with allergy to animal dander or animal-instigated asthma. 2. Patient must not have undergone a bladder biopsy or limited (incomplete) TURBT within 3 weeks (21 days) of the MRI. |
Country | Name | City | State |
---|---|---|---|
United States | Cedars-Sinai Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Cedars-Sinai Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Proceed With MRI Imaging and Sequencing of Bladder Tumor | Number of participants who proceed with radiogenomics analysis with useable data, that is a preliminary signature related to MIBC. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03522155 -
Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies
|
N/A | |
Completed |
NCT06358599 -
The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy
|
||
Recruiting |
NCT06170177 -
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
|
||
Completed |
NCT04598724 -
Addressing Barriers to Palliative Care Use in Bladder Cancer
|